Skip to search formSkip to main contentSkip to account menu

levormeloxifene

Known as: 1-(2-(p-(trans-7-Methoxy-2,2-dimethyl-3-phenyl-4-chromanyl)phenoxy)ethyl)pyrrolidine 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Pyrrolidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Assessment of raloxifene, estradiol-17β, dl-ormeloxifene and levormeloxifene on thrombin activity
Abstract Background: Cancer is one of the leading causes of morbidity and mortality globally. Cancer-associated thrombosis is… 
2008
2008
The potential of hormones and selective oestrogen receptor modulators in preventing voiding dysfunction in rats
To investigate whether oestrogen, selective oestrogen receptor modulators (SERMs), and growth hormone (GH) can prevent the… 
Review
2006
Review
2006
What can be learned from the levormeloxifene experience?
Levormeloxifene is a selective estrogen receptor modulator that was developed as an alternative to estrogen replacement therapy… 
Review
2006
Review
2006
Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women.
Menopause, regardless of age at onset, is associated with a marked increase in coronary heart disease (CHD) risk. On the basis of… 
2005
2005
Differential Effects of Estrogen and Raloxifene on Messenger RNA and Matrix Metalloproteinase 2 Activity in the Rat Uterus
Abstract A detailed analysis of the differential effects of estrogen (E) compared to raloxifene (Ral), a selective estrogen… 
2003
2003
Associated response in bone mineral density and atherogenic lipid profile during treatment with two different selective estrogen receptor modulators: levormeloxifene and raloxifene
Objective: We recently demonstrated a correlation between the responses in two target areas, bone and lipids, during treatment… 
2003
2003
Adverse effects of a SERM (Levormeloxifene). Safety parameters and bone mineral density 12 months after treatment withdrawal.
Highly Cited
2001
Highly Cited
2001
Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy.
Three hundred and one healthy women between 45 and 65 yr of age and at least 1 yr postmenopausal were randomly assigned to 12… 
2001
2001
Therapeutic potential of oestrogen receptor ligands in development for osteoporosis
Accelerated bone loss secondary to loss of ovarian function at menopause is well recognised as a major risk factor for… 
2000
2000
Other selective oestrogen receptor modulators (SERMs) in development.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)